TAVR is a minimally invasive, catheter-based procedure to replace the function of the aortic valve. Indicated for patients at intermediate or greater risk for open heart surgery, TAVR may be an excellent option for certain patients because the prevalence of aortic stenosis and co-morbidities may increase the risks associated with surgical aortic valve replacement (SAVR).
The Evolut™ TAVR System is the only TAVR platform on the market that demonstrates significantly better outcomes in all-cause mortality or stroke over surgery in high-risk patients at 3 years.1
Deeb, et. al, J Am Coll Cardiol. 3-Year Outcomes in High-Risk Patients Who Underwent Surgical or Transcatheter Aortic Valve Replacement, 2016 Jun 7;67(22):2565-74.
Williams, et. al, presented at ACC 2018, 1-year outcomes with the Evolut PRO Self-Expanding Repositionable Transcatheter Aortic Valve with Pericardial Wrap
Petrossian, et. al, presented at ACC 2018, Clinical Outcomes at 5 Years Following Self-Expanding Transcatheter Aortic Valve Replacement in the CoreValve US Extreme Risk Pivotal Trial.